PharmaEssentia Corporation announced it has entered into a license agreement with WuXi Biologics Ireland Limited to obtain the global exclusive rights to research, develop, manufacture and commercialize a myeloid immune checkpoint antibody candidate. PharmaEssentia will take over responsibility for the subsequent preclinical and clinical development efforts. As part of the agreement, PharmaEssentia will pay license fees to WuXi Biologics, including an upfront payment upon signing, future research, development, regulatory and sales milestones payments, and sales royalties.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
424 TWD | +1.68% | +3.79% | +22.54% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.54% | 4.37B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- 6446 Stock
- News PharmaEssentia Corporation
- Pharmaessentia Corporation Enters into Exclusive Global License Agreement with Wuxi Biologics for A Myeloid Immune Checkpoint Antibody Candidate